Global Information
회사소개 | 문의 | 비교리스트

중국의 리툭시맙(Rituximab) 시장

Investigation Report on Chinese Rituximab Market, 2018-2022

리서치사 China Research and Intelligence
발행일 2018년 07월 상품 코드 296864
페이지 정보 영문 30 Pages
가격
US $ 2,200 ₩ 2,658,000 Unprintable PDF (Single User License)
US $ 3,300 ₩ 3,988,000 Printable & Editable PDF (Enterprisewide License)


중국의 리툭시맙(Rituximab) 시장 Investigation Report on Chinese Rituximab Market, 2018-2022
발행일 : 2018년 07월 페이지 정보 : 영문 30 Pages

리툭시맙(Roche의 MabThera, Genentech의 Rituxan)은 종양 치료제로서 1997년에 승인을 받은 CD20 항원에 대한 키메라 단일클론항체입니다. B세포 림프종 치료에 매우 효과적이며 뛰어난 내성을 보이고 있습니다. 전세계 리툽시맙 매출은 2010년에 50억 3,400만 달러, 2011년에 61억 4,000만 달러, 2012년에 71억 4,300만 달러로 꾸준한 증가세를 보였고, 2014년에는 80억 달러 이상에 달했습니다.

중국의 리툭시맙(Rituximab) 시장에 대해 조사 분석했으며, 주요 제조업체의 시장 점유율, 병원 시장에서의 판매 가격, 병원 시장에서의 시장 점유율(제형별), 자가면역질환 발증률, 제네릭의약품 제조 스케줄, 시장 전망 등의 정보를 전해드립니다.

제1장 리툭시맙 관련 개념

  • 적응
  • 세계 시장의 판매 상황

제2장 중국의 리툭시맙 시장 개요

  • 특허 상황
  • 주요 제조업체
  • 시장 규모

제3장 중국의 리툭시맙 매출 분석

  • 총매출
  • 매출 : 지역별

제4장 중국 리툭시맙 주요 제조업체의 시장 점유율 분석

  • 시장 점유율 : 매출별
  • 시장 점유율 : 판매량별

제5장 중국의 리툭시맙(제형별) 시장 규모 분석

  • 시장 점유율 : 매출 및 제형별
  • 시장 점유율 : 판매량 및 제형별

제6장 중국 병원 시장에서의 리툭시맙 기준 가격

  • Hoffmann-La Roche, Inc.
  • Roche Diagnostics
  • Shanghai Roche Pharmaceutical Co., Ltd.

제7장 중국의 리툭시맙 주요 제조업체

  • Hoffmann-La Roche, Inc.
  • Roche Diagnostics
  • Shanghai Roche Pharmaceutical Co., Ltd.

제8장 중국의 리툭시맙 시장 전망

  • 비호지킨 림프종 및 자가면역질환 발생률 예측
  • 리툭시맙 시장 규모 예측
  • 리툭시맙 경쟁 패턴 예측

도표

LSH 14.03.13

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Description

Rituximab (Roche's trade name: Rituxan) is a human-mouse chimeric anti-CD20 monoclonal antibody that was approved for the treatment of tumors in 1997. With the deep understanding of B cells and their mechanisms of action, the therapeutic range of Rituximab has expanded from B-cell malignancies to autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, idiopathic thrombocytopenic purpura, etc.

The global sales of Rituximab have been very mature. In fiscal year 2017, Rituximab recorded a revenue of CHF 7.388 billion, a YOY increase of 1.21%. The drug was mostly used for tumor treatment. In fiscal year 2017, the sales value from tumor treatment reached CHF 5.832 billion, increasing by 0.15% YOY, and the sales value from the treatment of autoimmune diseases reached CHF 1.556 billion, increasing by 5.35% YOY. In China, Roche's Rituximab is mainly used to treat non-Hodgkin lymphoma.

As a major malignant lymphoma, non-Hodgkin lymphoma takes up a much larger proportion of malignant lymphoma than Hodgkin's disease in China. The incidence of non-Hodgkin's lymphoma has risen rapidly from 20 cases per 1 million people at the end of the 20th century to 70 cases per 1 million people today. Autoimmune diseases may affect organs such as the central nervous system, lungs, liver and kidneys, cause dysfunction or even failure of organs, and ultimately threaten life. Statistics show that there are about 30 to 40 million people suffering from autoimmune diseases in China, which leads to a growing demand for Rituximab. In 2017, the sales value of Rituximab exceeded CNY 1 billion in China.

According to CRI, by Jul. 2018, there has been no China-made Rituximab on the market, and the market is monopolized by the products of Roche and its subsidiary Genentech. Several domestic manufacturers have applied for approval to produce generic Rituximab. It is expected that generic Rituximab will be launched after 2020. There is still a large growth potential for the Chinese Rituximab market.

Topics Covered:

  • Development environment of Chinese Rituximab market
  • Sales of Rituximab in China
  • Prices of Rituximab in China
  • Progress of generic Rituximab in China
  • Prospects of Chinese Rituximab Market, 2018-2022

Table of Contents

Table of Contents

1 Basic Concepts of Rituximab

  • 1.1 Indications for Rituximab
  • 1.2 Development History of Rituximab in China
  • 1.3 Governmental Approval of Rituximab in China

2 Sales of Rituximab in China, 2013-2017

  • 2.1 Sales Value of Rituximab
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value in Parts of China
  • 2.2 Sales Volume of Rituximab
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume in Parts of China
  • 2.3 Sales of Rituximab by Dosage Form

3 Major Rituximab Manufacturers in China, 2013-2017

  • 3.1 Market Share of Major Rituximab Manufacturers in China
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 Roche
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Roche's Rituximab in China
  • 3.3 Genentech
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Genentech's Rituximab in China

4 Prices of Rituximab in China, 2017-2018

  • 4.1 Average Prices of Rituximab in China
    • 4.1.1 National Average Price
    • 4.1.2 Average Price by Region
  • 4.2 Prices of Major Manufacturers' Rituximab in China
    • 4.2.1 Price of Roche's Rituximab in China
    • 4.2.2 Price of Genentech's Rituximab in China

5 Prospects of Chinese Valsartan Market, 2018-2022

  • 5.1 Factors Influencing Rituximab Development in China
    • 5.1.1 Driving Forces and Market Opportunities
    • 5.1.2 Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Competition Pattern

Selected Charts

  • Chart Rituximab Products Approved to Market in China by 2018
  • Chart Sales Value of Rituximab in China, 2013-2017
  • Chart Sales Value of Rituximab by Region in China, 2013-2017
  • Chart Market Share of Rituximab Manufacturers by Sales Value in China, 2013-2017
  • Chart Prices of Roche's Rituximab in Key Regions of China, 2017-2018
  • Chart Prices of Genentech's Rituximab in Key Regions of China, 2017-2018
  • Chart Forecast on Sales of Rituximab in China, 2018-2022
  • Chart Generic Rituximab in China
Back to Top
전화 문의
F A Q